The mechanisms accounting for the higher dose requirements are not known, but may be due, at least in part, to the more abundant blood supply in the spleen compared to the subcutaneous space or alternatively to differences in the cellular and molecular mechanisms responsible for mediating the effects of COX-2 inhibition on tumour growth and metastasis. Here, PTGS2 is linked to neoplasm.